Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference

September 1, 2021 at 8:30 AM EDT

BASEL, Switzerland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the 2021 Baird Global Healthcare Conference on September 15, 2021. Company management will participate in a fireside chat at 2:35 p.m. Eastern Time in addition to participating in small group investor meetings.

Investors and the general public are invited to listen to the Baird fireside chat, which will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.

About Myovant Sciences 
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Founded in 2016, we have two FDA-approved products. ORGOVYX® (relugolix) was approved by the U.S. Food and Drug Administration in 2020 as the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and relugolix is also under regulatory review in Europe for men with advanced prostate cancer. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) was approved in 2021 in the U.S. as MYFEMBREE® as the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, and by the European Commission as RYEQO® for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. The therapy has also completed Phase 3 registration-enabling studies for women with endometriosis and is being assessed for the prevention of pregnancy. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor Contact:
Ryan Crowe
Vice President, Investor Relations
Myovant Sciences, Inc.
+1 (650) 781-9106
investors@myovant.com

Media Contact:
Albert Liao 
Director, Corporate Communications
Myovant Sciences, Inc.
+1 (650) 410-3055
media@myovant.com 


Primary Logo

Source: Myovant Sciences, Inc.